info@targetmol.com    Tel: (857) 239-0968 / (617) 419-7131
Home > FLT3
FLT3
Cat.No. Product Name Information Area
T7007 UNC-2025 UNC-2025 is a potent and orally bioavailable dual MER/FLT3 inhibitor with IC50 of 0.7... Others
T6756 AMG 925 AMG 925 is a potent and orally bioavailable dual FLT3/CDK4 inhibitor with IC50 of 1 n... Others
T6479 Dovitinib (TKI258) Lactate Dovitinib (TKI258) Lactate is the Lactate of Dovitinib, which is a multitargeted RTK ... Cardiovascular System
T6193 Dovitinib (TKI-258) Dilactic Acid Dovitinib Dilactic acid (TKI258 Dilactic acid) is the Dilactic acid of Dovitinib, whi... Cancer
T6138 TCS 359 TCS 359 is a potent FLT3 inhibitor with IC50 of 42 nM. Cancer
T6132 ENMD-2076 L-(+)-Tartaric acid ENMD-2076 L-(+)-Tartaric acid is the tartaric acid of ENMD-2076, selective activity a... Cancer
T6020 Pacritinib (SB1518) Pacritinib (SB1518) is a potent and selective inhibitor of Janus Kinase 2 (JAK2) and ... Cancer
T3078 SGI-1776 free base SGI-1776 free base is a novel ATP competitive inhibitor of Pim1 with IC50 of 7 nM in ... Cancer
T3072 XL019 XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, exhibiting >50-fo... Cancer
T3065 TG101209 TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM, less potent to Flt3 and RET... Cancer
T2699 BMS-777607 BMS-777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50 of 3.9 ... Endocrine system
T2696 PRT062607 hydrochloride PRT062607 (P505-15, BIIB057) hydrochloride is a novel, highly selective Syk inhibitor... Cardiovascular System
T2653 SB1317 SB1317/TG02 is a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 ... Cancer
T2640 DCC-2036 (Rebastinib) DCC-2036 (Rebastinib) is a conformational control Bcr-Abl inhibitor for Abl1(WT) and ... Cardiovascular System
T2638 Gandotinib (LY2784544) LY2784544(gandotinib) is a potent JAK2 inhibitor with IC50 of 3 nM, effective in JAK2... Cancer
T2624 OSI-930 OSI-930 is a potent inhibitor of Kit, KDR and CSF-1R with IC50 of 80 nM, 9 nM and 15 ... Cancer
T2620 G-749 G-749 is a novel and potent FLT3 inhibitor with IC50 of 0.4 nM, 0.6 nM and 1 nM for F... Cardiovascular System
T2516 Amuvatinib(MP470) Amuvatinib (MP-470) is a potent and multi-targeted inhibitor of c-Kit, PDGFRα and Flt... Cancer
T2514 Linifanib Linifanib (ABT-869) is a novel, potent ATP-competitive VEGFR/PDGFR inhibitor for KDR,... Cancer
T2509 Tozasertib VX-680 (Tozasertib, MK-0457) is a pan-Aurora inhibitor, mostly against Aurora A with ... Cancer
T2358 ENMD-2076 ENMD-2076 has selective activity against Aurora A and Flt3 with IC50 of 14 nM and 1.8... Cancer
T2349 BMS-754807 BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.... Cancer
T2341 KW-2449 KW-2449 is a multiple-targeted inhibitor, mostly for Flt3 with IC50 of 6.6 nM, modest... Cancer
T2272 BPR1J-097 BPR1J-097 is a novel small molecule FLT-3 inhibitor(IC50=11±7 nM) with promising in v... Cancer
T2115 Pexidartinib Pexidartinib (PLX3397) is an oral, potent mutil-targeted receptor tyrosine kinase inh... Cancer
T2066 Quizartinib Quizartinib (AC220) is a second-generation FLT3 inhibitor for Flt3(ITD/WT) with IC50 ... Cancer
T2051 FLT3-IN-1 FLT3-IN-1 is a novel potent and selective Flt3 inhibitor with IC50 of 10 nM; against ... Cancer
T1995 Fedratinib (SAR302503, TG101348) Fedratinib (SAR302503, TG101348) is a selective inhibitor of JAK2 with IC50 of 3 nM i... Other
T1938 FLT3-IN-2 FLT3-IN-2 is a FLT3 inhibitor with IC50 of < 1 μM, detailed information refer to WO 2... Cancer
T1667 Tandutinib Tandutinib (MLN518, CT53518) is a potent FLT3 antagonist with IC50 of 0.22 μM, also i... Cancer
1